Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Lawley Lori D	2. Issuer Name and Ticker or Trading Symbol NEWLINK GENETICS CORP [ (NLNK) ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Principal Accounting Officer
(Last) (First) (Middle) C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DR.	3. Date of Earliest Transaction (MM/DD/YYYY) 7/31/2019
(Street) AMES, IA 50010 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$52.64	7/31/2019		D			10000	4/20/2016	4/19/2025	Common Stock	10000.0	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		1633		⁽²⁾	7/31/2026	Common Stock	1633.0	⁽¹⁾	1633	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		868		⁽²⁾	7/31/2026	Common Stock	868.0	⁽¹⁾	868	D
Stock Option (Right to Buy)	$24.42	7/31/2019		D			2000	2/1/2017	1/31/2026	Common Stock	2000.0	⁽³⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		472		⁽²⁾	7/31/2026	Common Stock	472.0	⁽³⁾	472	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		98		⁽²⁾	7/31/2026	Common Stock	98.0	⁽³⁾	98	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		98		⁽⁴⁾	7/31/2026	Common Stock	98.0	⁽³⁾	98	D
Stock Option (Right to Buy)	$10.78	7/31/2019		D			3334	9/9/2016	8/8/2026	Common Stock	3334.0	⁽⁵⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		1111		⁽²⁾	7/31/2026	Common Stock	1111.0	⁽⁵⁾	1111	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		487		⁽²⁾	7/31/2026	Common Stock	487.0	⁽⁵⁾	487	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		70		⁽⁴⁾	7/31/2026	Common Stock	70.0	⁽⁵⁾	70	D
Stock Option (Right to Buy)	$12.68	7/31/2019		D			2352	2/1/2018	1/31/2027	Common Stock	2352.0	⁽³⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		115		⁽²⁾	7/31/2026	Common Stock	115.0	⁽³⁾	115	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		311		⁽⁴⁾	7/31/2026	Common Stock	311.0	⁽³⁾	311	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		360		⁽²⁾	7/31/2026	Common Stock	360.0	⁽³⁾	360	D
Stock Option (Right to Buy)	$8.86	7/31/2019		D			10000	12/1/2018	11/30/2027	Common Stock	10000.0	⁽⁵⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		729		⁽²⁾	7/31/2026	Common Stock	729.0	⁽⁵⁾	729	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		3021		⁽⁴⁾	7/31/2026	Common Stock	3021.0	⁽⁵⁾	3021	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		1250		⁽²⁾	7/31/2026	Common Stock	1250.0	⁽⁵⁾	1250	D
Stock Option (Right to Buy)	$7.85	7/31/2019		D			2000	3/1/2019	3/8/2028	Common Stock	2000.0	⁽⁵⁾	0	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		146		⁽²⁾	7/31/2026	Common Stock	146.0	⁽⁵⁾	146	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		563		⁽⁴⁾	7/31/2026	Common Stock	563.0	⁽⁵⁾	563	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		187		⁽²⁾	7/31/2026	Common Stock	187.0	⁽⁵⁾	187	D
Stock Option (Right to Buy)	$1.77	7/31/2019		A		105		⁽⁴⁾	7/31/2026	Common Stock	105.0	⁽⁵⁾	105	D

Explanation of Responses:
(1)	On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every four cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
(2)	The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
(3)	On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every three cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
(4)	The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
(5)	On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Lawley Lori D C/O NEWLINK GENETICS CORPORATION 2503 SOUTH LOOP DR. AMES, IA 50010			Principal Accounting Officer

Signatures
/s/ Ryan Trytten, attorney-in-fact		8/2/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.